Cerus (CERS) Competitors $1.25 +0.01 (+0.80%) As of 02:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CERS vs. STAA, OSUR, UTMD, ANIK, WST, COO, ALGN, MMSI, HAE, and ICUIShould you be buying Cerus stock or one of its competitors? The main competitors of Cerus include STAAR Surgical (STAA), OraSure Technologies (OSUR), Utah Medical Products (UTMD), Anika Therapeutics (ANIK), West Pharmaceutical Services (WST), Cooper Companies (COO), Align Technology (ALGN), Merit Medical Systems (MMSI), Haemonetics (HAE), and ICU Medical (ICUI). These companies are all part of the "health care supplies" industry. Cerus vs. Its Competitors STAAR Surgical OraSure Technologies Utah Medical Products Anika Therapeutics West Pharmaceutical Services Cooper Companies Align Technology Merit Medical Systems Haemonetics ICU Medical Cerus (NASDAQ:CERS) and STAAR Surgical (NASDAQ:STAA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends. Does the media prefer CERS or STAA? In the previous week, STAAR Surgical had 12 more articles in the media than Cerus. MarketBeat recorded 23 mentions for STAAR Surgical and 11 mentions for Cerus. STAAR Surgical's average media sentiment score of 0.38 beat Cerus' score of 0.23 indicating that STAAR Surgical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cerus 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral STAAR Surgical 6 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is CERS or STAA more profitable? Cerus has a net margin of -9.81% compared to STAAR Surgical's net margin of -42.45%. STAAR Surgical's return on equity of -16.11% beat Cerus' return on equity.Company Net Margins Return on Equity Return on Assets Cerus-9.81% -33.77% -9.32% STAAR Surgical -42.45%-16.11%-12.54% Which has more risk & volatility, CERS or STAA? Cerus has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500. Comparatively, STAAR Surgical has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Do analysts recommend CERS or STAA? Cerus presently has a consensus price target of $3.50, indicating a potential upside of 178.88%. STAAR Surgical has a consensus price target of $20.67, indicating a potential downside of 24.67%. Given Cerus' stronger consensus rating and higher possible upside, equities analysts plainly believe Cerus is more favorable than STAAR Surgical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cerus 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00STAAR Surgical 0 Sell rating(s) 10 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders & institutionals believe in CERS or STAA? 78.4% of Cerus shares are owned by institutional investors. Comparatively, 96.7% of STAAR Surgical shares are owned by institutional investors. 3.4% of Cerus shares are owned by insiders. Comparatively, 0.6% of STAAR Surgical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has preferable earnings & valuation, CERS or STAA? STAAR Surgical has higher revenue and earnings than Cerus. STAAR Surgical is trading at a lower price-to-earnings ratio than Cerus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCerus$180.27M1.33-$20.92M-$0.10-12.55STAAR Surgical$313.90M4.33-$20.21M-$1.93-14.22 SummaryCerus beats STAAR Surgical on 9 of the 16 factors compared between the two stocks. Get Cerus News Delivered to You Automatically Sign up to receive the latest news and ratings for CERS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CERS vs. The Competition Export to ExcelMetricCerusMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$240.58M$10.36B$5.49B$9.81BDividend YieldN/A2.00%4.59%4.13%P/E Ratio-12.5519.6729.9725.18Price / Sales1.3321.10444.82102.90Price / CashN/A23.6424.8128.01Price / Book4.053.468.695.83Net Income-$20.92M$211.77M$3.26B$265.22M7 Day Performance-1.95%3.78%0.45%0.77%1 Month Performance-13.45%6.40%3.13%1.99%1 Year Performance-38.48%-7.54%45.69%27.37% Cerus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CERSCerus2.9356 of 5 stars$1.26+0.8%$3.50+178.9%-41.8%$240.58M$180.27M-12.55290Earnings ReportAnalyst RevisionSTAASTAAR Surgical2.7751 of 5 stars$18.49+4.1%$18.00-2.7%-28.9%$879.58M$313.90M-12.841,211OSUROraSure Technologies1.9312 of 5 stars$3.12+3.7%$3.00-3.8%-33.9%$225.15M$185.83M-7.43840UTMDUtah Medical Products3.3759 of 5 stars$56.78+3.3%N/A-15.6%$178.49M$40.90M15.18180ANIKAnika Therapeutics4.574 of 5 stars$8.77+1.5%$18.00+105.2%-68.0%$124.57M$119.91M-2.11300WSTWest Pharmaceutical Services4.606 of 5 stars$238.34-0.4%$320.71+34.6%-16.5%$17.20B$2.89B35.6810,600Positive NewsCOOCooper Companies3.4449 of 5 stars$71.45+0.8%$96.73+35.4%-23.9%$14.17B$3.90B34.6816,000News CoverageALGNAlign Technology4.9601 of 5 stars$137.77+0.9%$215.00+56.1%-37.3%$9.90B$4.00B23.2320,945Positive NewsBuyback AnnouncementMMSIMerit Medical Systems4.5345 of 5 stars$85.38+0.7%$107.00+25.3%-7.1%$5.02B$1.36B43.347,400Positive NewsHAEHaemonetics4.9322 of 5 stars$76.26+2.0%$97.30+27.6%-31.8%$3.59B$1.36B23.043,023News CoverageEarnings ReportAnalyst DowngradeICUIICU Medical4.6108 of 5 stars$130.06+2.1%$192.67+48.1%-29.2%$3.14B$2.38B-33.9615,000Earnings ReportAnalyst Downgrade Related Companies and Tools Related Companies STAA Competitors OSUR Competitors UTMD Competitors ANIK Competitors WST Competitors COO Competitors ALGN Competitors MMSI Competitors HAE Competitors ICUI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CERS) was last updated on 8/12/2025 by MarketBeat.com Staff From Our Partners#1 Pre-IPO Opportunity For 2025 [Take Action Now!]James Altucher has scored 37X and even 60X returns on past pre-IPO deals. But now he says a much bigger opport...Paradigm Press | SponsoredThe stealth altcoin the financial world is underestimatingThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn your "dead money" into $306+ monthly (starting this month)Turn your "dead money" into $306+ monthly (starting this month) I've been tracking a financial revolution t...Investors Alley | SponsoredMy shocking meeting in Washington, D.C.After a shocking discovery in D.C., Jeff Brown is revealing: President Trump’s “Project MAFA” Get a look...Brownstone Research | SponsoredBig Changes Coming in August — Is Your IRA Ready?Banks aren’t waiting for the headlines to catch up. They’ve already started moving their wealth out of pape...Reagan Gold Group | SponsoredSilver Demand Is Exploding—and Supply Can’t Keep UpElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerus Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Cerus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access